Japan’s Eisai Looks To MGI Pharma Acquisition For Growth
This article was originally published in PharmAsia News
Executive Summary
Japan's Eisai is looking to expanded sales of MGI Pharma in its home country of the United States for the acquiring company's own improvement. MGI's CEO Lonnie Moulder expects Eisai's acquisition to be symbiotic, with Eisai's sales staff combining with MGI's to put 900 representatives on the ground in the United States. Eisai looks to the MGI tie to counteract a reduction it faces in its own drug pipeline as patents on key products expire. Other Japanese drug makers have chosen to merge with each other. (Click here for more - a subscription may be required
You may also be interested in...
Eisai To File Dacogen sNDA for Out-Patient MDS, Despite Less Than Stellar Survival Data
TOKYO - As part of its strategy to reinforce its oncology and innovative pharmaceutical products, Eisai July 1 said its ongoing clinical trial comparing Dacogen with best supportive care in elderly patients with myelodysplastic syndromes, a bone marrow disease, had registered results that would enable the company to submit for applying the treatment on an out-patient basis, instead of in-hospital treatment
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.